CBD oil has strong evidence for one specific use: reducing seizures in certain forms of epilepsy. For everything else people commonly buy it for, including pain, anxiety, and sleep, the evidence ranges from mixed to weak. That gap between what’s proven and what’s marketed is the central issue with CBD.
Where CBD Has Clear Evidence: Epilepsy
The FDA approved a pharmaceutical-grade CBD product in 2018 for treating severe forms of epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. The clinical trial data behind that approval is substantial. Patients with Dravet syndrome experienced a 39% median reduction in seizure frequency compared to 13% for placebo. In Lennox-Gastaut trials, seizure reductions ranged from 37% to 43% depending on the dose, compared to about 17% to 22% for placebo.
This is the only FDA-approved use for CBD, and the product used in those trials was a purified, precisely dosed formulation, not the kind of CBD oil sold at gas stations or wellness shops.
CBD for Anxiety: Promising but Incomplete
Anxiety is the most common reason people try CBD oil, and there is some clinical support for it. A systematic review of human trials found evidence that a single dose of CBD can reduce symptoms of social anxiety disorder. Some controlled trials have shown anxiolytic effects with acute dosing.
The problem is consistency. The doses, formulations, and delivery methods vary enormously across studies, making it hard to draw firm conclusions about how much to take or how reliably it works. There’s no established therapeutic dose for anxiety the way there is for the epilepsy indication. If CBD does help with anxiety, the effect appears to be real but poorly defined in terms of practical guidance.
CBD for Pain: Limited Support
Many people reach for CBD oil hoping it will help with chronic pain, particularly nerve pain or arthritis. The evidence here is disappointing. A Cochrane review looking specifically at CBD-dominant products for chronic neuropathic pain found no clear evidence that CBD achieved meaningful pain relief. Across five studies with over 200 participants, there was no significant difference between CBD and placebo for achieving either 30% or 50% pain reduction.
That doesn’t mean no individual has ever felt relief from CBD. But in controlled settings where researchers can separate real effects from placebo, CBD-dominant products haven’t demonstrated consistent pain benefits. Products combining CBD with THC show somewhat different results, but that’s a different question than whether CBD oil on its own works for pain.
CBD for Sleep: Mostly Placebo
A randomized controlled trial testing 150 mg of CBD nightly for insomnia found no significant differences from placebo on any major sleep measure. Time to fall asleep, total sleep duration, sleep efficiency, and number of nighttime awakenings were all statistically identical between the CBD and placebo groups. The one notable finding was that CBD users reported greater general well-being, suggesting the effects may be primarily psychological rather than physiological.
This aligns with a broader pattern in CBD research: people often feel better when taking it, but objective measurements frequently don’t confirm measurable changes. That doesn’t make the subjective improvement meaningless, but it does suggest expectation plays a significant role.
How CBD Works in the Body
CBD doesn’t work the way most people assume. Unlike THC, which binds directly to cannabinoid receptors in the brain, CBD has negligible affinity for those same receptors. Instead, it appears to act as an indirect modulator, influencing how other compounds interact with the body’s endocannabinoid system. It can also affect serotonin receptors, which may partly explain the anxiety-related findings.
One common misconception involves how you take it. Many people hold CBD oil drops under the tongue, believing this allows faster absorption through the mouth’s lining. A pharmacokinetic study comparing sublingual drops to capsules found no meaningful difference. Peak blood concentrations, time to reach those peaks (about four hours for both), and total absorption were essentially identical. The researchers concluded that CBD oil placed under the tongue is likely swallowed before any significant absorption occurs through the mouth, meaning sublingual drops and capsules work the same way.
Side Effects and Drug Interactions
CBD is generally well tolerated, but it’s not side-effect free. In clinical trials, the most common adverse effects at 10% incidence or higher were gastrointestinal symptoms (affecting about 60% of participants at therapeutic doses), sleepiness (17%), loss of appetite (17%), elevated liver enzymes (13%), and fatigue (11%). Diarrhea alone affected roughly 32% of CBD users in these studies compared to 14% on placebo.
The drug interaction profile is more concerning than most people realize. CBD is processed by the same liver enzymes that metabolize a long list of common medications. By inhibiting these enzymes, CBD can raise blood levels of SSRIs, tricyclic antidepressants, antipsychotics, beta-blockers, opioids, benzodiazepines, certain statins (atorvastatin and simvastatin), corticosteroids like prednisolone, anti-seizure medications, and common pain relievers including naproxen, tramadol, and celecoxib. If you take any prescription medication, CBD use is worth discussing with a pharmacist or prescriber, because the interaction potential is broad.
Most Products Don’t Contain What They Claim
Even if CBD worked perfectly for a given condition, you’d need the product to actually contain what the label says. A 2024 analysis of 202 CBD products sold in the United States found that 74% deviated from their labeled CBD potency by at least 10%. More than a quarter of products tested didn’t even meet the basic definition for the product type claimed on the packaging (full spectrum, broad spectrum, or isolate). Five products had no detectable CBD at all. Three broad-spectrum products, which are supposed to be THC-free, contained THC, with two exceeding the 0.3% legal threshold.
Contamination was also common. Heavy metals, most often lead, were detected in 44 of 202 products. Residual solvents from manufacturing appeared in 181 of 202 products. Pesticides were found in 30 products. While most contamination levels fell below regulatory thresholds, some did not. The CBD market has no uniform quality control standards, which means what you’re buying is largely a matter of trust.
The Regulatory Gap
CBD exists in a legal gray zone that explains much of the quality problem. The FDA has concluded that CBD cannot legally be sold as a dietary supplement because it was first studied as a drug ingredient before it entered the supplement market. That exclusion means CBD products sold online and in stores aren’t technically legal under federal food and drug law, yet enforcement has been minimal. In January 2023, the FDA acknowledged that existing regulatory frameworks don’t work for CBD and said it would work with Congress on a new approach. As of now, no new framework has been established, leaving the market largely unregulated.
This means no federal agency is routinely verifying that CBD products contain what they claim, are free from contaminants, or are safe for the conditions they’re implicitly marketed for. The burden falls entirely on the consumer to research brands, look for third-party testing certificates, and interpret lab results.